$1.26
+0.01 (+0.80%)
Open$1.25
Previous Close$1.25
Day High$1.28
Day Low$1.22
52W High$2.99
52W Low$0.87
Volume—
Avg Volume477.7K
Market Cap92.78M
P/E Ratio—
EPS$-0.50
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+123.8% upside
Current
$1.26
$1.26
Target
$2.82
$2.82
$1.78
$2.82 avg
$3.37
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 19.42M | 19.36M | 17.02M |
| Net Income | -2,266,322 | -2,263,432 | -1,770,857 |
| Profit Margin | -11.7% | -11.7% | -10.4% |
| EBITDA | -3,805,934 | -3,485,255 | -2,994,447 |
| Free Cash Flow | -1,809,844 | -1,626,073 | -1,604,802 |
| Rev Growth | +9.6% | -8.7% | +9.0% |
| Debt/Equity | 1.27 | 1.74 | 1.38 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |